18 Chapter 1 S39–S43 (2006). 25. LeDuc, J. W. & Barry, M. A. SARS, the first pandemic of the 21st Century1. Emerging Infectious Diseases 10, e26–e26 (2004). 26. De Wit, E., Van Doremalen, N., Falzarano, D. & Munster, V. J. SARS and MERS: recent insights into emerging coronaviruses. Nature Reviews Microbiology 14, 523–534 (2016). 27. Peiris, M. & Perlman, S. Unresolved questions in the zoonotic transmission of MERS. Current Opinion in Virology 52, 258–264 (2022). 28. Msemburi, W. et al. The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature 613, 130–137 (2023). 29. Taubenberger, J. K. & Morens, D. M. Influenza: The once and future pandemic. Public health reports 125, 15–26 (2010). 30. Paget, J., Marquet, R., Meijer, A. & Velden, K. van der. Influenza activity in Europe during eight seasons (19992007): an evaluation of the indicators used to measure activity and an assessment of the timing, length and course of peak activity (spread) across Europe. BMC Infectious Diseases 7, 141 (2007). 31. Wolfe, N. D., Dunavan, C. P. & Diamond, J. Origins of major human infectious diseases. Nature 447, 279–283 (2007). 32. Hassell, J. M., Begon, M., Ward, M. J. & Fèvre, E. M. Urbanization and Disease Emergence: Dynamics at the WildlifeLivestockHuman Interface. Trends in Ecology & Evolution 32, 55–67 (2017). 33. Clark, H. et al. Transforming or tinkering: the world remains unprepared for the next pandemic threat. Lancet (London, England) 399, 1995–1999 (2022). 34. Burgos, R. M. et al. The race to a COVID-19 vaccine: opportunities and challenges in development and distribution. Drugs in Context 10, (2021). 35. Docherty, A. B. et al. Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ (Clinical research ed.) 369, m1985 (2020). 36. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 Preliminary Report. New England Journal of Medicine NEJMoa2021436 (2020) doi:10.1056/ NEJMoa2021436. 37. Tulchinsky, T. H. John Snow, Cholera, the Broad Street Pump; Waterborne Diseases Then and Now. in 77–99 (Elsevier, 2018). doi:10.1016/B978-0-12-804571-8.00017-2. 38. Morabia, A. Epidemiology’s 350th Anniversary: 1662-2012. Epidemiology (Cambridge, Mass.) 24, 179–183 (2013). 39. Ginsberg, J. et al. Detecting influenza epidemics using search engine query data. Nature 457, 1012–1014 (2009). 40. Gilbert, G. L., Degeling, C. & Johnson, J. Communicable Disease Surveillance Ethics in the Age of Big Data and New Technology. Asian Bioethics Review 11, 173–187 (2019). 41. Imanishi, M. et al. Typhoid fever acquired in the United States, 19992010: epidemiology, microbiology, and use of a spacetime scan statistic for outbreak detection. Epidemiology and Infection 143, 2343–2354 (2015). 42. Buda, S., Tolksdorf, K., Schuler, E., Kuhlen, R. & Haas, W. Establishing an ICD-10 code based SARI-surveillance in Germany description of the system and first results from five recent influenza seasons. BMC Public Health 17, 612 (2017). 43. Ho, A. et al. Adeno-Associated Virus 2 Infection in Children with Non-A-E Hepatitis. http:// medrxiv.org/lookup/doi/10.1101/2022.07.19.22277425 (2022) doi:10.1101/2022.07.19.22277425. 44. Martin, W. Making valid causal inferences from observational data. Preventive Veterinary Medicine 113, 281–297 (2014). 45. Raita, Y., Camargo, C. A., Liang, L. & Hasegawa, K. Big data, data science, and causal inference: A primer for clinicians. Frontiers in Medicine 8, 678047 (2021). 46. Hernan, M. A. & Robins, J. M. Causal Inference: What If. (Boca Raton: Chapman & Hall/CRC., 2020). 47. Ciani, O., Manyara, A. M., Chan, A.-W., Taylor, R. S. & on behalf of the SPIRIT-SURROGATE/ CONSORT-SURROGATE project group. Surrogate endpoints in trials: a call for better reporting. Trials 23, 991 (2022).
RkJQdWJsaXNoZXIy MTk4NDMw